VR09 Cell Line: an EBV-positive Lymphoblastoid Cell Line with in Vivo Characteristics of Diffuse Large B Cell Lymphoma of Activated B-cell Type

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Jan 4

PMID 23285191

Citations 5

Authors

Ilaria Nichele

Alberto Zamo

Anna Bertolaso

Francesco Bifari

Martina Tinelli

Marta Franchini

Roberta Stradoni

Fiorenza Aprili

Giovanni Pizzolo

Mauro Krampera

Affiliations

Soon will be listed here.

Abstract

Background: small B-cell neoplasms can show plasmacytic differentiation and may potentially progress to aggressive lymphoma (DLBCL). Epstein-Barr virus (EBV) infection may cause the transformation of malignant cells in vitro.

Design And Method: we established VR09 cell line with plasmacytic differentiation, obtained from a case of atypical, non-CLL B-cell chronic lymphoproliferative disease with plasmacytic features. We used flow cytometry, immunohistochemistry, polymerase chain reaction, cytogenetic analysis and florescence in situ hybridization in the attempt at thoroughly characterizing the cell line. We showed VR09 tumorigenic potential in vivo, leading to the development of activated DLBCL with plasmacytic features.

Results: VR09 cells displayed plasmacytic appearance and grew as spherical tumors when inoculated subcutaneously into immunodeficient Rag2(-/-) γ-chain(-/-) mice. VR09 cell line and tumors displayed the phenotype of activated stage of B cell maturation, with secretory differentiation (CD19+ CD20+ CD79a+ CD79b+/- CD138+ cyclin D1- Ki67 80% IgM+ IgD+ MUM1+ MNDA+ CD10- CD22+ CD23+ CD43+ K+, λ- Bcl2+ Bcl6-) and they presented episomal EBV genome, chromosome 12 trisomy, lack of c-MYC rearrangement and Myd88 gene mutation, presence of somatic hypermutation in the VH region, and wild-type p53.

Conclusion: This new EBV-positive cell line may be useful to further characterize in vivo activated DLBCL with plasmacytic features.

Citing Articles

Functional Targets for Epstein-Barr Virus BART MicroRNAs in B Cell Lymphomas.

Fachko D, Goff B, Chen Y, Skalsky R Cancers (Basel). 2024; 16(20).

PMID: 39456631 PMC: 11506495. DOI: 10.3390/cancers16203537.

In Vitro Diffuse Large B-Cell Lymphoma Cell Line Models as Tools to Investigate Novel Immunotherapeutic Strategies.

Kubacz M, Kusowska A, Winiarska M, Bobrowicz M Cancers (Basel). 2023; 15(1).

PMID: 36612228 PMC: 9818372. DOI: 10.3390/cancers15010235.

Epstein-Barr virus perpetuates B cell germinal center dynamics and generation of autoimmune-associated phenotypes .

SoRelle E, Reinoso-Vizcaino N, Horn G, Luftig M Front Immunol. 2022; 13:1001145.

PMID: 36248899 PMC: 9554744. DOI: 10.3389/fimmu.2022.1001145.

Single-cell RNA-seq reveals transcriptomic heterogeneity mediated by host-pathogen dynamics in lymphoblastoid cell lines.

SoRelle E, Dai J, Bonglack E, Heckenberg E, Zhou J, Giamberardino S Elife. 2021; 10.

PMID: 33501914 PMC: 7867410. DOI: 10.7554/eLife.62586.

Vitamin D Receptor Expression in Plasmablastic Lymphoma and Myeloma Cells Confers Susceptibility to Vitamin D.

Gascoyne D, Lyne L, Spearman H, Buffa F, Soilleux E, Banham A Endocrinology. 2016; 158(3):503-515.

PMID: 28001444 PMC: 5460784. DOI: 10.1210/en.2016-1802.

References

Montes-Moreno S, Gonzalez-Medina A, Rodriguez-Pinilla S, Maestre L, Sanchez-Verde L, Roncador G . Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica. 2010; 95(8):1342-9. PMC: 2913083. DOI: 10.3324/haematol.2009.016113. View

Tarrand J, Keating M, Tsimberidou A, OBrien S, LaSala R, Han X . Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia. Cancer. 2010; 116(4):880-7. DOI: 10.1002/cncr.24839. View

Tsimberidou A, Keating M . Richter syndrome: biology, incidence, and therapeutic strategies. Cancer. 2004; 103(2):216-28. DOI: 10.1002/cncr.20773. View

Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M . A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000; 95(6):2084-92. View

Choi W, Weisenburger D, Greiner T, Piris M, Banham A, Delabie J . A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009; 15(17):5494-502. PMC: 7289055. DOI: 10.1158/1078-0432.CCR-09-0113. View

Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D . MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res. 1999; 23(2):127-36. DOI: 10.1016/s0145-2126(98)00154-4. View

van Rijn R, Simonetti E, Hagenbeek A, Bonyhadi M, Storm G, Martens A . Quantitative assessment of human T lymphocytes in RAG2(-/-)gammac(-/-) mice: the impact of ex vivo manipulation on in vivo functionality. Exp Hematol. 2007; 35(1):117-27. DOI: 10.1016/j.exphem.2006.09.018. View

Chen M . Epstein-barr virus, the immune system, and associated diseases. Front Microbiol. 2011; 2:5. PMC: 3109484. DOI: 10.3389/fmicb.2011.00005. View

Campo E, Swerdlow S, Harris N, Pileri S, Stein H, Jaffe E . The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117(19):5019-32. PMC: 3109529. DOI: 10.1182/blood-2011-01-293050. View

10.

Varghese A, Sayala H, Evans P, OConnor S, Patmore R, Hillmen P . Development of EBV-associated diffuse large B-cell lymphoma in Waldenstrom macroglobulinemia and mantle cell lymphoma. Leuk Lymphoma. 2008; 49(8):1618-9. DOI: 10.1080/10428190802123481. View

11.

Drexler H, Matsuo A, MacLEOD R . Continuous hematopoietic cell lines as model systems for leukemia-lymphoma research. Leuk Res. 2000; 24(11):881-911. DOI: 10.1016/s0145-2126(00)00070-9. View

12.

Zamo A, Ott G, Katzenberger T, Adam P, Parolini C, Scarpa A . Establishment of the MAVER-1 cell line, a model for leukemic and aggressive mantle cell lymphoma. Haematologica. 2006; 91(1):40-7. View

13.

Brunelli M, Eccher A, Gobbo S, Ficarra V, Novara G, Cossu-Rocca P . Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol. 2007; 21(1):1-6. DOI: 10.1038/modpathol.3800967. View

14.

Brest P, Lapaquette P, Souidi M, Lebrigand K, Cesaro A, Vouret-Craviari V . A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet. 2011; 43(3):242-5. DOI: 10.1038/ng.762. View

15.

Altmann M, Hammerschmidt W . Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol. 2005; 3(12):e404. PMC: 1283332. DOI: 10.1371/journal.pbio.0030404. View

16.

Rossi D, Gaidano G . Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol. 2009; 27(1):1-10. DOI: 10.1002/hon.880. View

17.

Ngo V, Young R, Schmitz R, Jhavar S, Xiao W, Lim K . Oncogenically active MYD88 mutations in human lymphoma. Nature. 2010; 470(7332):115-9. PMC: 5024568. DOI: 10.1038/nature09671. View

18.

Shinkai Y, Rathbun G, Lam K, Oltz E, Stewart V, Mendelsohn M . RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992; 68(5):855-67. DOI: 10.1016/0092-8674(92)90029-c. View

19.

Puente X, Pinyol M, Quesada V, Conde L, Ordonez G, Villamor N . Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011; 475(7354):101-5. PMC: 3322590. DOI: 10.1038/nature10113. View

20.

Lin P, Mansoor A, Bueso-Ramos C, Hao S, Lai R, Medeiros L . Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Clinicopathologic features of 12 cases. Am J Clin Pathol. 2003; 120(2):246-53. DOI: 10.1309/R01V-XG46-MFCD-VNHL. View